Alembic Inks Licensing Agreement With Belgian Co

Mumbai: Alembic Ltd has forayed into a licensing agreement with Belgian drugmaker UCB for its Novel Drug Delivery Platform for epilepsy drug Keppra XR (Levetiracetam extended release tablets). As per the terms of the agreement, Alembic will give the technology to decrease the dosage for the twice-a-day Keppra drug to make it a once-a-day tablet. The tablet will then be sold in dosages of 500 mg, 1000 mg and 1500 mg and will be called Keppra XR. Alembic will get milestone payments of $11 million and additionally get royalty payments on future worldwide net sales of the Keppra drug, subject to necessary legal and regulatory approvals.